Metabolic Risk Factors
Rimonabant reduced body weight and improved metabolic risk factors in high-risk patients
Published in Obesity and Diabetes Week, January 2nd, 2006
According to recent research published in the New England Journal of Medicine, "Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia."
J.P. Despres and colleagues at the Laval Hospital...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathogenesis
High sugar intake is linked to lower AIR, indicating poor beta cell function and diabetes risk - Diabetes Pathogenesis
Lower catecholamine-induced lipolysis and HSL expression are linked to obesity - Diabetes Pathogenesis
Prediabetic rats lacking CCK-1 receptors display altered taste functions - Diabetes Pathogenesis
The mechanisms behind diabetes and hypertension onset in hereditary obesity are presented - Obesity Epidemiology
Epicardial fat is significantly related to obesity-related insulin resistance - Adverse Drug Reaction
Exenatide lowered plasma glucose when given by continuous SC infusion over 23 h - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
